ClinicalTrials.gg
RecruitingNCT07430540Updated Aug 28, 2026

Optimising Colorectal Cancer Patient Pathways

An interventional study of Additional FIT testing in Colorectal Cancer and Significant Bowel Pathology, sponsored by University of Edinburgh. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by University of Edinburgh · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 388 studies in Colorectal Neoplasms with a site in United Kingdom — 72 open to participants now, 100 under way, 18 of them phase 3. Colorectal Neoplasms · United Kingdom.

Planned enrollment
30th of 299
1,000 · median 150
Started
2026
with 8 others
No phase
64 of 388
12 open now
Primary completion
2028-03
later than 66 of 99 live
Registered
382nd of 388
by date

Among the 388 studies in Colorectal Neoplasms with a site in United Kingdom, this one is the 30th largest by planned enrollment of the 299 interventional ones that give a count, is one of 9 that started in 2026, is one of 64 with no phase, reaches primary completion later than 66 of the 99 other live ones, and was the 382nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

72 of the 388 studies in Colorectal Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 388 studies in Colorectal Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

Bowel cancer (colorectal cancer) is the 4th most common cancer in Scotland. Approximately 4,000 cases are diagnosed annually. Cancer-related deaths in Scotland are higher than other UK nations. Improving the early detection of bowel cancer, and therefore survival, is important.

The majority of bowel cancers are diagnosed within secondary-care (colorectal surgery unit). Upon GP referral to secondary-care, patients provide stool samples which are analysed for microscopic blood (FIT; faecal immunohistochemical test). Patients with a single positive result are more likely to have bowel cancer (0.2% risk if no blood detected, but 8.4% if detected). A positive test triggers further investigation, either CT scan or colonoscopy depending on the result. Currently, colonoscopy and radiology services throughout Scotland are under significant pressure causing delays.

Only 2% of patients referred to secondary-care are diagnosed with bowel cancer, and most colonoscopies performed do not yield significant findings. We have shown that performing two repeated FITs upon referral improves cancer pick-up rate (sensitivity) and reduces missed cancers. We successfully implemented this in NHS Lothian and contributed to national guidelines. Optimising allocation of investigations and therefore improving the detection-rate (specificity) may reduce colonoscopy demand, saving vital resources.

NHS Lothian patients referred to secondary-care with symptoms concerning of bowel cancer will be included. \~1,000 included patients will undertake extra FIT tests in study whether changes in stool blood levels over time help better allocate investigations and improve test specificity. With these results, a new secondary-care pathway will be designed. Health economic analysis will determine costs and benefits of implementing a new pathway and the risks of missed cancers. The project also provides infrastructure to collect additional stool and blood samples to develop new tests that improve bowel cancer detection.

Read the detailed description

Study design:

This research study will perform multiple FIT testing in a prospective cohort of patients referred through the NHS Lothian CRC USoC/urgent pathway. This pathway is co-ordinated by the Colorectal Surgery team and the Interface Triage Office ('FIT office') situated at the Western General Hospital.

Current standard patient care:

A patient with 'red-flag' lower GI symptoms presenting to their GP is referred to the CRC USoC pathway. Urgent referrals for patients with similar symptoms outwith primary care are also included.

Referrals are sent to the NHS Lothian FIT office. Receipt of referral triggers the postage of 1 FIT collection kit (Minaris Medical Co. Ltd) and information leaflet to the patient. Within a few days, a second FIT collection kit and information leaflet is sent to the patient. The patient is instructed to provide a stool sample for FIT analysis, and to hand the samples into their GP practice. The patient is instructed to leave around 4 days between 1st and 2nd sample collection.

FIT samples are sent from the GP to the UKAS accredited NHS Tayside Blood Sciences laboratory based in Ninewells Hospital (Dundee) where samples are analysed to ISO15189 standards using the HM-JACKarc analyser (Minaris Medical Co. Ltd). Results are automatically transferred from NHS Tayside to the patient's electronic health record within NHS Lothian. The NHS Lothian FIT office monitor referrals and incoming FIT results day-to-day. A follow-up call is made to the patients if 10 days elapse from postage of the FIT kit without upload of a FIT result.

The highest result of the two FITs dictates patient management. Results range from \<10 to ≥400 µgHb/g. There are 3 main categories:

  1. Highest FIT result \<10 µgHb/g: Patient referrals are sent to Consultant Colorectal Surgeons for review - the majority of these patients receive a clinical safety netting letter, however, \~30% undergo CT colonography or colonoscopy.
  2. Highest FIT result 10-79 µgHb/g: A CT colonography is requested for the patient by the NHS Lothian FIT office. Results of this are sent to the Duty Consultant Colorectal Surgeon. If the patient is young or presents with rectal bleeding, a colonoscopy is requested instead.
  3. Highest FIT result ≥80 µgHb/g: If clinically appropriate (deemed by GP within referral), a colonoscopy is requested for the patient by the NHS Lothian FIT office. Results are sent to the Duty Consultant Colorectal Surgeon.

If patients have two negative results they will receive a standardised letter from the Consultant providing safety netting. Otherwise, patients will subsequently receive correspondence from the relevant department with instructions of their planned investigation e.g. colonoscopy letter and pack from Endoscopy department, or similar information pack from Radiology department. Following investigation, patients are then appropriately managed based on investigative findings by the clinical team.

Implementation of intervention:

The clinical and research teams will monitor the FIT results from USoC and urgent referrals. Patients who have provided 2 FIT samples will be included. Patients with 2 negative results (\<10 µgHb/g) will be excluded.

Eligible patients will be contacted by a member of the research team after both FIT results have been returned and a clinical decision of investigation has been made by the clinical team (i.e. CT colonography or colonoscopy). If they are agreeable to take part in the study, they will be sent a research study information pack containing patient information sheets (PIS), additional FIT sample kits with instructions and a consent form with a prepaid envelope for return of consent form. The patient's GP will be sent a letter containing study details, what participation involves and any impact on clinical care.

The research study will deploy additional multiple FIT testing. Participants will be asked to provide a weekly FIT sample for 3 weeks - until they undergo colonic investigation. Patients will be advised to submit their collected stool sample to their GP for delivery to NHS Tayside, as what is carried out within the standard pathway. FIT results will be uploaded to the patient's EHR within NHS Lothian. In order to ensure adequate patient and sample recruitment, participants will be called one week into recruitment to discuss any concerns and encourage sample collection.

The additional 3 FIT results are unlikely to impact clinical care. Results will be monitored by the research team as they are received by the FIT office. Patients will continue with standard clinical care based on their 2 initial FIT results, as detailed above. Collection of samples should not be taken at the time of bowel prep for colonic investigations. There may be a small proportion of cases in which the additional FIT tests (tests 3-5) return a significantly higher FIT value than tests 1-2. This relates to a specific situation in which patients with initial FIT results of \<80 µgHb/g return an additional FIT result ≥80 µgHb/g. In the first instance they would have been scheduled a CT colonography as per our USoC/urgent pathway. Upon identifying a result of ≥80 µgHb/g, the research team will contact the relevant clinician to highlight this result, and as per our clinical pathway, recommend a colonoscopy to be performed. Conversely, there will be no de-escalation of pathway management should the additional tests are lower than the initial 2 FIT tests. Patients will not be routinely informed of their additional FIT results unless they are significantly higher than tests 1-2 or if the patient contacts the research team to enquire.

Patients will be included within our study for 10-year follow-up, to allow for data collection purposes (no further intervention will take place), in particular for cancer-related outcomes.

Additional sample collection:

The prospective intervention study represents a unique opportunity to collect samples for potential biomarkers that can aid early detection. Metabolomic analysis of patient faeces and blood serum has shown to improve CRC detection. The results of faecal and plasma short chain fatty acid (SCFA) analysis and plasma lipidomics can be used in combination with traditional FIT analysis to improve overall specificity for CRC. SCFAs are by-products from the gut microbiota digestion of starches and are altered in patients with CRC. These changes are detectable in both faeces and in blood serum. Furthermore, cf- and ct-DNA has been showed to have high sensitivity in the detection of early colorectal cancer.

Symptomatic patients scheduled for colonoscopy will only be included as attendance at endoscopy provides an opportunity for additional sample collection.

Additional faecal and blood samples will be stored at -80°C in a secure location in the Colon Cancer Genetic Group laboratories at the University of Edinburgh (UoE) Institute of Genetics and Cancer (IGC). Gas chromatography will be applied to analyse SCFA/lipid structure and concentration levels within samples, which will take place at the University of Glasgow. cf- and ct-DNA analysis will take place locally at the University of Edinburgh.

Recruitment:

Our study recruitment will take place for 1 year. Recruitment figures are based on pathway data. During 2024, 2,000 symptomatic patients were referred, and had at least one positive FIT result following submission of two FITs. CRC prevalence in this cohort is 0.077%.

There are no study comparators to estimate drop-out over five tests. The RFIT return rate was 64% and 57% for two and three FITs, respectively. Furthermore, in comparison to previous research within the unit (Gerrard et al, 2023), all patients within the proposed study will have a positive FIT and awaiting investigation. Thus, participants may have invested interest in providing more samples. Local data and experience signifies the importance of a patient follow-up call to encourage sample collection, which is incorporated into the research plan.

We anticipate around 25% of patients will not meet study eligibility, answer the phone or participate. A further estimated 25% will not submit additional FIT tests. Therefore, we predict a total of \~1,000 patients to submit five FIT tests over a 1-year period (50% of relevant cohort).

03

Conditions studied

  • Colorectal Cancer
  • Significant Bowel Pathology

Keywords

  • colorectal cancer
  • Multiple testing
  • Diagnostic accuracy
  • Faecal Immunohistochemical Test
  • qFIT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients referred to the NHS Lothian USoC CRC pathway or an urgent referral with 'red-flag' symptoms, and with a positive FIT on referral will be included.
  • Referred from start date of study, for up to 1 year

Exclusion criteria

Exclusion Criteria:

  • Two negative FITs on referral
  • Patients referred with a palpable rectal or abdominal mass
  • Previous history of CRC or IBD, or under polyp surveillance
  • Known to have genetic hereditary condition predisposing patient to increased risk of CRC (e.g. Lynch, FAP, etc).
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Additional FIT testing

    Additional (3) FITs

    Diagnostic Test: Additional FIT testing

Interventions

  • Diagnostic testAdditional FIT testing

    Additional (3) FIT tests

06

What researchers measure

Primary outcomes

  1. Pathway diagnostic accuracy

    Diagnostic accuracy of multiple FIT testing pathway (sensitivity, specificity, NNI)

    Time frame: One year

Secondary outcomes

  1. Cost-per diagnosis

    Cost per diagnosis within the multiple FIT pathway

    Time frame: 1 year

  2. Re-referral rate

    Re-referral rate to the service

    Time frame: 2 years

  3. Interval CRC rate

    Rate of interval CRC following pathway management

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Flahault A, Cadilhac M, Thomas G. Sample size calculation should be performed for design accuracy in diagnostic test studies. J Clin Epidemiol. 2005 Aug;58(8):859-62. doi: 10.1016/j.jclinepi.2004.12.009. PubMed 16018921 ↗
  • Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021 May 18;325(19):1978-1998. doi: 10.1001/jama.2021.4417. PubMed 34003220 ↗
  • Seum T, Frick C, Cardoso R, Bhardwaj M, Hoffmeister M, Brenner H. Potential of pre-diagnostic metabolomics for colorectal cancer risk assessment or early detection. NPJ Precis Oncol. 2024 Oct 27;8(1):244. doi: 10.1038/s41698-024-00732-5. PubMed 39462072 ↗
  • Farkas NG, Palyvos L, O'Brien JW, Yu KS, Pigott C, Whyte M, Jourdan I, Rockall T, Fraser CG, Benton SC. The repeat FIT (RFIT) study: Does repeating faecal immunochemical tests provide reassurance and improve colorectal cancer detection? Colorectal Dis. 2024 Sep;26(9):1711-1719. doi: 10.1111/codi.17132. Epub 2024 Aug 13. PubMed 39136046 ↗
  • Gerrard AD, Maeda Y, Noble C, Gunn F, Porteous L, Cheesbrough R, Thomson A, Dunlop MG, Din FVN; Edinburgh Colorectal Group. Clinical impact of double-faecal immunochemical testing following implementation into standard triage and investigation of primary care referrals in patients with lower gastrointestinal symptoms. BJS Open. 2025 Sep 8;9(5):zraf098. doi: 10.1093/bjsopen/zraf098. PubMed 41061132 ↗
  • Lemmon E, Hanna C, Diernberger K, Paterson HM, Wild SH, Ennis H, Hall PS. Variation in colorectal cancer treatment and outcomes in Scotland: real world evidence from national linked administrative health data. Int J Popul Data Sci. 2024 Feb 20;9(1):2179. doi: 10.23889/ijpds.v6i1.2179. eCollection 2024. PubMed 38476269 ↗
  • Farkas N, O'Brien JW, Palyvos L, Maclean W, Benton S, Rockall T, Jourdan I. The increasing burden of the 2-week wait colorectal cancer pathway in a single centre: the impact of faecal immunochemical tests. Ann R Coll Surg Engl. 2024 Apr;106(4):338-343. doi: 10.1308/rcsann.2022.0138. Epub 2023 Jan 23. PubMed 36688865 ↗
  • Cubiella J, Salve M, Diaz-Ondina M, Vega P, Alves MT, Iglesias F, Sanchez E, Macia P, Blanco I, Bujanda L, Fernandez-Seara J. Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria. Colorectal Dis. 2014 Aug;16(8):O273-82. doi: 10.1111/codi.12569. PubMed 24456168 ↗
  • Bailey JA, Ibrahim H, Bunce J, Chapman CJ, Morling JR, Simpson JA, Humes DJ, Banerjea A. Quantitative FIT stratification is superior to NICE referral criteria NG12 in a high-risk colorectal cancer population. Tech Coloproctol. 2021 Oct;25(10):1151-1154. doi: 10.1007/s10151-021-02466-z. Epub 2021 Jul 14. PubMed 34263362 ↗
  • Pin-Vieito N, Tejido-Sandoval C, de Vicente-Bielza N, Sanchez-Gomez C, Cubiella J. Faecal immunochemical tests safely enhance rational use of resources during the assessment of suspected symptomatic colorectal cancer in primary care: systematic review and meta-analysis. Gut. 2022 May;71(5):950-960. doi: 10.1136/gutjnl-2021-324856. Epub 2021 Jun 9. PubMed 34108236 ↗
  • Saw KS, Liu C, Xu W, Varghese C, Parry S, Bissett I. Faecal immunochemical test to triage patients with possible colorectal cancer symptoms: meta-analysis. Br J Surg. 2022 Feb 1;109(2):182-190. doi: 10.1093/bjs/znab411. PubMed 34907419 ↗
  • Gerrard AD, Maeda Y, Miller J, Gunn F, Theodoratou E, Noble C, Porteous L, Glancy S, MacLean P, Pattenden R, Dunlop MG, Din FVN; Edinburgh Colorectal Group. Double faecal immunochemical testing in patients with symptoms suspicious of colorectal cancer. Br J Surg. 2023 Mar 30;110(4):471-480. doi: 10.1093/bjs/znad016. PubMed 36785496 ↗
  • Cubiella J, Vega P, Salve M, Diaz-Ondina M, Alves MT, Quintero E, Alvarez-Sanchez V, Fernandez-Banares F, Boadas J, Campo R, Bujanda L, Clofent J, Ferrandez A, Torrealba L, Pinol V, Rodriguez-Alcalde D, Hernandez V, Fernandez-Seara J; COLONPREDICT study investigators. Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients. BMC Med. 2016 Aug 31;14(1):128. doi: 10.1186/s12916-016-0668-5. PubMed 27580745 ↗
  • Perkmann T, Koller T, Perkmann-Nagele N, Ozsvar-Kozma M, Eyre D, Matthews P, Bown A, Stoesser N, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S, Aletaha D, Sieghart D, Quehenberger P, Marculescu R, Mucher P, Radakovics A, Klausberger M, Duerkop M, Holzer B, Hartmann B, Strassl R, Leitner G, Grebien F, Gerner W, Grabherr R, Wagner OF, Binder CJ, Haslacher H. Increasing test specificity without impairing sensitivity: lessons learned from SARS-CoV-2 serology. J Clin Pathol. 2023 Nov;76(11):770-777. doi: 10.1136/jcp-2022-208171. Epub 2022 Aug 30. PubMed 36041815 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2028, 21 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 21 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 24, 2026
StartActual
Jun 5, 2026
Primary completionEst.
Mar 22, 2028
CompletionEst.
Mar 22, 2037
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07430540
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Jun 5, 2026
Primary completion
Mar 22, 2028 (estimated)
Completion
Mar 22, 2037 (estimated)
Last update
Aug 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion